The Valley Desk

Clinical trial reportCancer immunology, immunotherapy : CIIPublished

A phase 1 study of VAC85135, a neoantigen vaccine regimen targeting calreticulin and JAK2 mutations, in combination with ipilimumab in patients with myeloproliferative neoplasms

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Clinical trial report
Venue
Cancer immunology, immunotherapy : CII
Published
Subject terms
Humans; Myeloproliferative Disorders; Calreticulin; Cancer Vaccines; Antigens, Neoplasm; Mutation; Adult; Aged; Aged, 80 and over; Middle Aged; Female; Male
PubMed ID
43052517
PubMed Central ID
PMC13782046
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal